Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ProShares UltraPro S&P500 — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while ProShares UltraPro S&P500 trades at $140.08. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | UPRO | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $28.06 | $150.93 |
52-Week Low | $20.06 | $89.29 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
UPRO, the ProShares UltraPro S&P 500 ETF, trades at $144.41, up 2.64% with a bullish technical outlook from moving averages. The leveraged ETF faces neutral sentiment from oscillators while tracking S&P 500 performance. Recent news highlights sector rotation from tech stocks and mixed analyst views on S&P 500 targets ranging from 8,000 to 8,800 by year-end 2026.
The leveraged structure amplifies both gains and losses, making UPRO suitable for short-term trading amid expected S&P 500 volatility. Key risks include Fed policy uncertainty and sector rotation pressures, while opportunities exist if the S&P 500 reaches analyst targets. Earnings season performance and AI sector momentum remain critical catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
